Abstract
Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Current Molecular Pharmacology
Title:Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs)
Volume: 5
Author(s): Tom Hsun-Wei Huang and Basil D. Roufogalis
Affiliation:
Keywords: Cardiometabolic syndrome, diabetes mellitus, herbal and traditional natural medicines, peroxisome proliferator-activated receptor-γ
Abstract: Cardiometabolic syndrome is a mixture of interrelated risk factors predisposing individuals to elevated risk of atherosclerotic cardiovascular disease and type 2 diabetes mellitus. Nuclear receptors, specifically peroxisome proliferator-activated receptors (PPARs), were identified to play a pivotal role in the regulation of metabolic homeostasis. However, with rosiglitazone currently under intense scrutiny great concerns have arisen regarding the safety of the thiazolidinedione PPAR-γ agonist family as a whole. This review discusses the current concern with PPAR-γ agonists by exploring if PPARs can still be considered worth pursuing as a viable target for cardiovascular diseases. We examine current research focusing on identifying ligands that are dual and pan-PPAR agonists, selective PPAR-γ modulators, PPAR-β/δ agonists and that are of natural origin.
Export Options
About this article
Cite this article as:
Hsun-Wei Huang Tom and D. Roufogalis Basil, Healing the Diabetic Heart: Modulation of Cardiometabolic Syndrome through Peroxisome Proliferator Activated Receptors (PPARs), Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020241
DOI https://dx.doi.org/10.2174/1874467211205020241 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy
Current Diabetes Reviews Effect of Vaginal Delivery on Lactose Content of Human Milk
Current Pediatric Reviews Correlation Between Insulin Levels and Thyroid Hormones in Diabetic Animals After Caffeine Consumption Associated with Exercise
Current Nutrition & Food Science Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets A Systematic Review of Lifestyle Modification and Glucose Intolerance in the Prevention of Type 2 Diabetes
Current Diabetes Reviews GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data
Current Alzheimer Research Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]
Current Pharmaceutical Design Inhalation Delivery of Protein Therapeutics
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Diabetes Mellitus-Cell Transplantation and Gene Therapy Approaches.
Current Molecular Medicine Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Outcomes in Pregnant Patients with Subclinical Hypothyroidism and Thyroid Autoimmunity: A Critical Appraisal of Recent Randomized Controlled Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Hormones and their Receptors Bridge Fat and Bone Metabolisms
Current Signal Transduction Therapy An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry Anti-Inflammatory Role of Thyroid Hormones on Rat Air Pouch Model of Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)